<![CDATA[Janssen 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=29201>Sat, 25 Apr 2026 19:18:35 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA®▼ (D/C/F/TAF) in Treatment-Naïve Adults with HIV-1]]>https://www.newswire.co.kr/newsRead.php?no=878126Wed, 31 Oct 2018 11:35:00 +0900<![CDATA[Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1]]>https://www.newswire.co.kr/newsRead.php?no=869683Wed, 23 May 2018 19:20:00 +0900<![CDATA[Janssen Announces Positive CHMP Opinion for JULUCA™▼ (dolutegravir/rilpivirine)]]>https://www.newswire.co.kr/newsRead.php?no=866513Mon, 26 Mar 2018 11:30:00 +0900<![CDATA[Janssen’s New Darunavir-Based Single Tablet Regimen SYMTUZA® Shows Positive Outcome in Treatment of Antiretroviral-Naïve HIV Patients]]>https://www.newswire.co.kr/newsRead.php?no=858537Thu, 26 Oct 2017 09:15:00 +0900<![CDATA[Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV]]>https://www.newswire.co.kr/newsRead.php?no=853801Fri, 28 Jul 2017 09:40:00 +0900<![CDATA[얀센 ‘심투자’, CHMP ‘긍정 의견’ 받아… HIV 치료를 위한 최초의 다루나비르 기반 단일복합정]]>https://www.newswire.co.kr/newsRead.php?no=853802Fri, 28 Jul 2017 09:40:00 +0900<![CDATA[Janssen Announces Phase 3 Pivotal Study Results for Darunavir-Based Complete Treatment Regimen]]>https://www.newswire.co.kr/newsRead.php?no=853698Wed, 26 Jul 2017 13:50:00 +0900<![CDATA[Data Published in The Lancet Shows High Efficacy at 96 Weeks for First Investigational Two-Drug, Long-Acting Injectable HIV Regimen]]>https://www.newswire.co.kr/newsRead.php?no=853586Mon, 24 Jul 2017 18:10:00 +0900<![CDATA[Pimodivir Alone or in Combination with Oseltamivir Demonstrated a Significant Reduction in Viral Load in Adults with Influenza A]]>https://www.newswire.co.kr/newsRead.php?no=851583Thu, 15 Jun 2017 11:15:00 +0900